Sinemet: Clinical Trials

13 trials of Sinemet, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 13
Phase 22Completed 2

Follow Sinemet: new trials by email Literature Review of Sinemet trials Research Report on Sinemet

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg - Parkinsonian Signs in Older Persons
Phase 1 / Phase 2CompletedUniversity of Michigan52024-10-292026-04-14
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1 - Parkinsonian Signs in Older Persons
Phase 1 / Phase 2CompletedUniversity of Michigan132024-03-152025-06-17
Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis
carbidopa-levodopa, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Phase 1CompletedWashington University School of Medicine152019-05-132022-07-11
Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
CVT-301, Sinemet - Parkinson's Disease
Phase 1CompletedAcorda Therapeutics232019-03-052019-08-02
PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
PF-06412562, Standard of Care Placebo - Parkinson Disease
Phase 1CompletedMilton S. Hershey Medical Center82018-09-242019-07-31
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
Opicapone, Carbidopa Levodopa - Parkinson Disease
Phase 1CompletedNeurocrine Biosciences162018-02-082019-03-22
Pharmacokinetic of Levodopa Study in Healthy Males
Levodopa, carbidopa, ODM-104 - Parkinson Disease
Phase 1CompletedOrion Corporation, Orion Pharma202017-04-192017-09-26
Dose-finding Pharmacokinetic Study in Healthy Males
Levodopa, Carbidopa, ODM-104 - Healthy Volunteers
Phase 1CompletedOrion Corporation, Orion Pharma562017-02-212021-05-27
Pharmacokinetic Study in Healthy Volunteers
levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone - Parkinson's Disease
Phase 1CompletedOrion Corporation, Orion Pharma152015-08-012016-01-14
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
Levodopa/Carbidopa (Sinemet) - Parkinson's Disease
Phase 1CompletedNeuroDerm Ltd.62015-04-012015-07-01
Pharmacokinetic Study in Healthy Males
levodopa, carbidopa, ODM-104 - Parkinson's Disease
Phase 1CompletedOrion Corporation, Orion Pharma202014-11-012015-02-18
Levodopa Concentration Profile With Stalevo 75/125 mg
Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa) - Parkinson's Disease
Phase 1CompletedOrion Corporation, Orion Pharma202009-12-012010-08-13
Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome
Levodopa/Carbidopa (4:1) - Angelman Syndrome
Phase 1CompletedBoston Children's Hospital162009-01-012016-11-21

Conditions studied

Parkinson Disease (8)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Angelman Syndrome (1)  ·  Motor Neuron Disease (1)

Sponsors

Orion Corporation, Orion Pharma (5)  ·  University of Michigan (2)  ·  Acorda Therapeutics (1)  ·  Boston Children's Hospital (1)  ·  Milton S. Hershey Medical Center (1)  ·  NeuroDerm Ltd. (1)  ·  Neurocrine Biosciences (1)  ·  Washington University School of Medicine (1)

Countries

United States (7)  ·  Finland (4)  ·  Germany (1)

Top investigators

Chatkaew Pongmala, PhD (2)  ·  Mika Scheinin, MD (2)  ·  Charles Oh, MD (1)  ·  Denis Strugala, DR.med. (1)  ·  Kimmo Ingman (1)  ·  Philip Evans, MBChB, MRCS (1)  ·  Timothy M Miller, MD, PhD (1)  ·  Wen-Hann Tan, BMBS (1)  ·  Xuemei Huang, MD, PhD (1)

Results publications

PMID 32482490, PMID 32986682, PMID 34032202

NIH funding

U01AG061393 (2)